Status:
UNKNOWN
Clinical Evaluation of the Serum Free Light Chain Analysis
Lead Sponsor:
Charlotte Toftmann Hansen
Conditions:
Multiple Myeloma
Eligibility:
All Genders
Brief Summary
Background: in patients with multiple myeloma there is a raised level of a protein, named M-protein. This M-protein is normally used to monitor disease status and evaluate response to treatment, as a ...
Eligibility Criteria
Inclusion
- diagnosis of multiple myeloma
- abnormal serum free light chains
- medical needs of anti-myeloma therapy
- receiving standard anti-myeloma therapy
Exclusion
- dialysis
- normal serum free light chains
- dementia
Key Trial Info
Start Date :
February 1 2011
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
February 1 2012
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT01423344
Start Date
February 1 2011
End Date
February 1 2012
Last Update
August 25 2011
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Department of Haematology, research unit
Odense C, Denmark, 5000